Integrating music, movement and stroke rehabilitation, MedRhythms raises $25M to develop and commercialize digital therapeutic

By SharpBrains | August 2, 2021

MedRhythms rais­es 25m to get patients back in tune after a stroke (TechCrunch): MedRhythms secured $25 mil­lion in Series B fund­ing to advance its dig­i­tal ther­a­py plat­form aimed at mea­sur­ing and improv­ing someone’s abil­i­ty to walk after they have expe­ri­enced a neu­ro­log­ic injury or dis­ease … Com­pa­ny co-founder and CEO Bri­an Har­ris was a neu­ro­log­ic music…

Read More

Neurostimulation device GammaSense by Cognito Therapeutics secures FDA Breakthrough Device Designation to explore Alzheimer’s Disease applications

By SharpBrains | January 14, 2021

Cog­ni­to Ther­a­peu­tics nets FDA break­through label for light, sound ther­a­py for Alzheimer’s dis­ease (Fierce Biotech): Using spe­cif­ic fre­quen­cies of flash­ing lights and sounds to stim­u­late the brain’s elec­tri­cal activ­i­ty, Cog­ni­to Ther­a­peu­tics believes it can help treat Alzheimer’s dis­ease by ener­giz­ing neu­rons and reac­ti­vat­ing the immune system.

Read More

Neuromodulation device Relivion gets FDA clearance to help patients with major depression who don’t benefit from antidepressant medications

By SharpBrains | August 12, 2020

Neu­rolief wins FDA break­through nod for wear­able neu­ro­mod for depres­sion (Mass Device): Neu­rolief announced today that it received FDA break­through device des­ig­na­tion for its Reliv­ion DP sys­tem for treat­ing major depres­sion. Reliv­ion is a wear­able, non-inva­­sive, mul­ti-chan­nel brain neu­ro­mod­u­la­tion device designed as an adjunc­tive treat­ment to phar­ma­ceu­ti­cal man­age­ment of major depres­sive dis­or­der (MDD) in adults…

Read More